- Home
- SUPV vs TSHA Comparison
SUPV vs TSHA Comparison
Compare SUPV & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPV
- TSHA
- Stock Information
- Founded
- SUPV 1887
- TSHA 2019
- Country
- SUPV Argentina
- TSHA United States
- Employees
- SUPV N/A
- TSHA N/A
- Industry
- SUPV Commercial Banks
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- SUPV Finance
- TSHA Health Care
- Exchange
- SUPV Nasdaq
- TSHA Nasdaq
- Market Cap
- SUPV 905.2M
- TSHA 728.4M
- IPO Year
- SUPV 2016
- TSHA 2020
- Fundamental
- Price
- SUPV $9.08
- TSHA $3.00
- Analyst Decision
- SUPV Buy
- TSHA Strong Buy
- Analyst Count
- SUPV 2
- TSHA 7
- Target Price
- SUPV $17.00
- TSHA $8.71
- AVG Volume (30 Days)
- SUPV 1.4M
- TSHA 2.6M
- Earning Date
- SUPV 08-13-2025
- TSHA 08-12-2025
- Dividend Yield
- SUPV 2.06%
- TSHA N/A
- EPS Growth
- SUPV N/A
- TSHA N/A
- EPS
- SUPV 0.09
- TSHA N/A
- Revenue
- SUPV $631,132,570.00
- TSHA $8,098,000.00
- Revenue This Year
- SUPV $30.41
- TSHA N/A
- Revenue Next Year
- SUPV $40.48
- TSHA N/A
- P/E Ratio
- SUPV $20.90
- TSHA N/A
- Revenue Growth
- SUPV N/A
- TSHA N/A
- 52 Week Low
- SUPV $6.75
- TSHA $1.05
- 52 Week High
- SUPV $19.75
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- SUPV 36.19
- TSHA 63.38
- Support Level
- SUPV $9.46
- TSHA $2.76
- Resistance Level
- SUPV $10.16
- TSHA $3.05
- Average True Range (ATR)
- SUPV 0.62
- TSHA 0.15
- MACD
- SUPV -0.16
- TSHA 0.00
- Stochastic Oscillator
- SUPV 1.40
- TSHA 75.51
About SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.